Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Biocept Inc BIOCQ

Healthcare Biotechnology

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Add To Watchlist

Recent & Breaking News (GREY:BIOCQ)

Biocept to Present at Molecular Medicine Tri-Con 2016

PR Newswire March 3, 2016

Biocept Issues Letter to Stockholders

PR Newswire March 1, 2016

Biocept to Hold 2015 Fourth Quarter and Full Year Conference Call on March 9

PR Newswire February 29, 2016

Biocept Secures Agreement with Preferred Provider Organization Prime Health Services

PR Newswire February 29, 2016

Data Demonstrating Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium

PR Newswire February 26, 2016

Biocept to Present at Upcoming Investment Conferences

PR Newswire February 2, 2016

Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference

PR Newswire January 25, 2016

Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois

PR Newswire January 12, 2016

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

PR Newswire January 7, 2016

Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund

PR Newswire December 22, 2015

Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis

Business Wire December 14, 2015

Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene

PR Newswire December 7, 2015

Biocept Gains Patent Protection in Hong Kong and Japan

PR Newswire November 30, 2015

Biocept to Present at LD Micro Main Event

PR Newswire November 25, 2015

Biocept Secures Agreements with Preferred Provider Organizations Fortified Provider Network and Three Rivers Provider Network

PR Newswire November 23, 2015

Biocept to Present Data Demonstrating a High Correlation of Biomarker Detection from its Liquid Biopsy Assays and Tissue Samples at the SelectBIO Biofluid Biopsies & High-Value Diagnostics 2015 Meeting

PR Newswire November 16, 2015

Biocept Expands Patent Protection in Europe

PR Newswire November 11, 2015

Biocept Reports Third Quarter 2015 Financial Results

PR Newswire November 5, 2015

Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy

Business Wire November 5, 2015

Biocept to Hold 2015 Third Quarter Conference Call on November 5

PR Newswire October 29, 2015